SPONSOR
Ohio State University Comprehensive Cancer Center
Total Trials
9
Recruiting
9
Phases
Phase 2, Phase 1
Conditions studied: Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Multiple MyelomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Multiple MyelomaCancer of the BreastChemotherapy-induced NeuropathyPancreatic CystEarly Stage Breast CarcinomaDyspneaBreast Atypical Ductal Hyperplasia
Ohio State University Comprehensive Cancer Center is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Multiple Myeloma.
The trial portfolio spans Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Ohio State University Comprehensive Cancer Center
How many clinical trials has Ohio State University Comprehensive Cancer Center sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by Ohio State University Comprehensive Cancer Center, of which 9 are actively recruiting participants. These trials cover conditions including Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma, Refractory B-Cell Non-Hodgkin Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Ohio State University Comprehensive Cancer Center research focus on?
Ohio State University Comprehensive Cancer Center clinical trials span Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Cancer of the Breast, and additional conditions. The research pipeline includes Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Ohio State University Comprehensive Cancer Center clinical trial?
To participate in a Ohio State University Comprehensive Cancer Center trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ohio State University Comprehensive Cancer Center trials with current recruitment status updated daily.
Clinical Trials by Ohio State University Comprehensive Cancer Center
NCT07609030
Recruiting
A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
NCT06749210 Phase 2
Recruiting
DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Cancer of the Breast
NCT03492151
Recruiting
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
Pancreatic Cyst
NCT07386444
Recruiting
Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
Early Stage Breast Carcinoma
NCT05178498
Recruiting
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
Breast Atypical Ductal Hyperplasia
NCT04780568 Phase 1
Recruiting
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Metastatic Lung Non-Small Cell Carcinoma
NCT06949943
Recruiting
Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery
Hematopoietic and Lymphatic System Neoplasm
NCT06500065
Recruiting
68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas
Soft Tissue Sarcoma
NCT07407647 Phase 2
Recruiting
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Anal Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology